Evolent Health, Inc.
EVH · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.57 | -0.06 | 3.09 | 0.70 |
| FCF Yield | -0.47% | 3.10% | -1.90% | 0.58% |
| EV / EBITDA | 22.39 | -166.50 | 66.73 | 43.04 |
| Quality | ||||
| ROIC | -1.95% | -1.97% | 0.08% | -4.32% |
| Gross Margin | 14.38% | 23.45% | 23.42% | 27.58% |
| Cash Conversion Ratio | -0.30 | -1.26 | 0.60 | -1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.63% | 29.33% | 13.50% | 9.73% |
| Free Cash Flow Growth | -105.38% | 328.07% | -462.64% | 130.12% |
| Safety | ||||
| Net Debt / EBITDA | 7.18 | -18.24 | 6.58 | 0.25 |
| Interest Coverage | -1.64 | -1.31 | 0.23 | -1.67 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 43.22 | 71.32 | 48.60 | -0.83 |